Strong Q4 2025 Performance and Full-Year Results
SOPHiA GENETICS, a global leader in AI-driven precision medicine, announced preliminary fourth-quarter and full-year 2025 financial results, highlighting robust momentum as the company advances its AI-powered platform across life sciences and clinical applications. While the company noted that the 2025 results are preliminary, management emphasized solid quarterly execution in Q4, underscoring a sustained trajectory into 2026.
Key highlights from the release point to continued demand for SOPHiA GENETICS’ data-driven solutions, driven by the growing adoption of AI-enabled analytics in genomics, oncology, and related health sectors. The company reiterated its commitment to expanding its global footprint, enabling more healthcare providers and researchers to leverage AI to unlock actionable insights from complex biological data.
2026 Guidance: 20-22% Revenue Growth
Looking ahead to 2026, SOPHiA GENETICS issued guidance targeting revenue growth in the range of 20-22%. The outlook reflects the company’s strategic initiatives to broaden product adoption, increase recurring software-generated revenue, and expand its services ecosystem. Management cited ongoing investments in platform enhancements, strategic partnerships, and international expansion as drivers of the planned growth rate.
Analysts and investors will be watching how the company balances top-line expansion with investments in R&D, go-to-market activities, and customer success initiatives designed to improve retention and lifetime value. The firm’s AI-first approach to data interpretation and its ability to unify disparate datasets across clinical and research settings position SOPHiA GENETICS to capture demand in both established and emerging markets.
Executive Transition: Ross Muken Named CEO
In a leadership transition, the company announced the appointment of Ross Muken as Chief Executive Officer. The move aims to align the company’s strategic priorities with an experienced public company leadership profile as SOPHiA GENETICS accelerates its growth and expands its global operations. The transition is described as a planned succession, signaling continuity in the company’s mission to democratize AI-driven insights in healthcare and life sciences.
Mr. Muken brings a track record of leadership, governance, and strategic execution in technology-enabled healthcare and financial markets. Under his leadership, SOPHiA GENETICS intends to maintain its focus on expanding its platform capabilities, strengthening partnerships, and delivering value to customers, patients, and stakeholders. The company will provide additional details on the transition timeline and leadership team updates in forthcoming disclosures.
<h2 Outlook and Strategic Focus
As SOPHiA GENETICS advances its AI-powered analytics platform, the company remains focused on delivering scalable solutions that improve diagnostic accuracy, accelerate research, and drive better clinical outcomes. The 2026 revenue guidance signals confidence in continued demand for cloud-based analytics, data sharing, and AI-driven interpretation across genomics, rare diseases, oncology, and population health initiatives.
Investors will also be attentive to how the leadership transition shapes the company’s long-term strategy, including potential new partnerships, international market penetration, and continued product innovation. SOPHiA GENETICS’ commitment to data security, regulatory compliance, and ethical AI practices will likely play a role in sustaining trust among customers and collaborators worldwide.
About SOPHiA GENETICS
SOPHiA GENETICS is a global leader in AI-driven precision medicine that empowers clinicians, researchers, and life science professionals to derive meaningful insights from complex biological data. The company’s platform integrates data analytics, machine learning, and data sharing to support diagnostic workflows, drug discovery, and translational research.
Contact and Additional Information
Further details regarding the financial results, 2026 guidance, and leadership transition will be provided in forthcoming investor communications and regulatory filings.
